142 related articles for article (PubMed ID: 1562122)
1. Torsades de pointes and ventricular fibrillation in a canine model of quinidine-induced QT prolongation.
Inoue H; Sugimoto T
Ann N Y Acad Sci; 1992 Jan; 644():93-102. PubMed ID: 1562122
[No Abstract] [Full Text] [Related]
2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
3. [Drug induced QT prolongation].
Altmann D; Eggmann U; Ammann P
Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
[TBL] [Abstract][Full Text] [Related]
4. QT interval prolongation and Torsades de Pointes in a patient receiving zolpidem and amiodarone.
Letsas KP; Filippatos GS; Kounas SP; Efremidis M; Sideris A; Kardaras F
Cardiology; 2006; 105(3):146-7. PubMed ID: 16449812
[No Abstract] [Full Text] [Related]
5. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
Lin JC; Quasny HA
Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
[TBL] [Abstract][Full Text] [Related]
6. [Long QT syndrome induced by cordaron and quinidine].
Mironchik EV; Dolgosheĭ TS; Liskovich TG; Madeshkina GA; Kokhkovski AB; Tyshchenko AD
Klin Med (Mosk); 2007; 85(3):69-71. PubMed ID: 17523411
[TBL] [Abstract][Full Text] [Related]
7. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.
Bertino JS; Owens RC; Carnes TD; Iannini PB
Clin Infect Dis; 2002 Mar; 34(6):861-3. PubMed ID: 11830802
[TBL] [Abstract][Full Text] [Related]
8. Ventricular fibrillation threshold in canine hearts with quinidine induced prolonged QT interval: effects of atrial pacing, isoproterenol, and lignocaine.
Inoue H; Matsuo H; Mashima S; Sugimoto T; Murao S
Cardiovasc Res; 1986 May; 20(5):349-57. PubMed ID: 3756976
[TBL] [Abstract][Full Text] [Related]
9. High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.
Wroblewski HA; Kovacs RJ; Kingery JR; Overholser BR; Tisdale JE
Antimicrob Agents Chemother; 2012 Aug; 56(8):4495-9. PubMed ID: 22615288
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of isoproterenol on quinidine induced torsade de pointes.
Yamamoto H; Bando S; Nishikado A; Shinohara A; Hamai K; Yamamoto K; Ikefuji H; Ito S
Tokushima J Exp Med; 1991 Jun; 38(1-2):1-4. PubMed ID: 1948996
[TBL] [Abstract][Full Text] [Related]
11. Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole.
Yamamoto K; Tamura T; Imai R; Yamamoto M
Toxicol Sci; 2001 Mar; 60(1):165-76. PubMed ID: 11222883
[TBL] [Abstract][Full Text] [Related]
12. Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning.
Chang JH; Weng TI; Fang CC
Am J Emerg Med; 2009 Oct; 27(8):1016.e1-3. PubMed ID: 19857426
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of isoproterenol, magnesium sulfate and verapamil for torsade de pointes].
Yamamoto H; Bando S; Nishikado A; Hamai K; Yamamoto K; Shinohara A
Kokyu To Junkan; 1991 Mar; 39(3):261-5. PubMed ID: 2047605
[TBL] [Abstract][Full Text] [Related]
14. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
[TBL] [Abstract][Full Text] [Related]
15. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced torsade de pointes.
Raehl CL; Patel AK; LeRoy M
Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
[TBL] [Abstract][Full Text] [Related]
17. Effects of bretylium tosylate on inhomogeneity of refractoriness and ventricular fibrillation threshold in canine hearts with quinidine-induced long QT interval.
Inoue H; Toda I; Nozaki A; Matsuo H; Sugimoto T
Cardiovasc Res; 1985 Oct; 19(10):655-60. PubMed ID: 4053141
[TBL] [Abstract][Full Text] [Related]
18. A canine model of torsades de pointes.
Leichter D; Danilo P; Boyden P; Rosen TS; Rosen MR
Pacing Clin Electrophysiol; 1988 Dec; 11(12):2235-45. PubMed ID: 2463611
[TBL] [Abstract][Full Text] [Related]
19. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
Lu HR; Gallacher DJ; Yan GX
J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
[TBL] [Abstract][Full Text] [Related]
20. QT interval prolongation and torsade de pointes associated with indapamide.
Letsas KP; Alexanian IP; Pappas LK; Kounas SP; Efremidis M; Sideris A; Kardaras F
Int J Cardiol; 2006 Oct; 112(3):373-4. PubMed ID: 16260053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
